<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610633</url>
  </required_header>
  <id_info>
    <org_study_id>PRO 50913</org_study_id>
    <nct_id>NCT03610633</nct_id>
  </id_info>
  <brief_title>Oxytocin and Stress Response in Alcohol Use Disorder</brief_title>
  <official_title>Impact of Oxytocin on Neurobiologic Substrates of Social Stress in Individuals With Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with alcohol use disorder (AUD) will complete one functional Magnetic Resonance
      Imaging (fMRI) scanning visit. Prior to the scan, individuals will receive a nasal spray of
      either 24 international units (IU) of oxytocin (OT), or placebo (PBO). During the scan, they
      will perform the Montreal Imaging Stress Task (MIST), a social stress task. Subjective
      craving and anxiety data will be collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants: Twenty-four individuals with AUD will be recruited through the Clinical Intake
      and Assessment (CIA) Core of the Alcohol Research Center (ARC). Screening and basic
      assessments will be conducted by the CIA Core to determine eligibility and suitability for
      participation in this pilot project. Each individual will sign an Institutional Review Board
      (IRB)-approved informed consent form.

      Study Visit Assessments: The Drinking Motives Questionnaire Revised will be used to assess
      motivation for drinking across four subscales: (1) coping motives; (2) social motives; (3)
      conformity motives; and (4) enhancement motives. The Form 90 will be used to assess daily
      alcohol consumption in the 90 days prior to the study visit and the time from last drink . A
      modification of the Within Session Rating Scale will be used to assess craving and mood.

      Study Visit Procedures: Participants will be asked to arrive at the Addiction Sciences
      Division on the study visit day. Female participants will have their urine tested for
      pregnancy. Females who test positive for pregnancy will be excluded. All participants will be
      tested for drugs of abuse and alcohol. Patients testing positive for drugs, with the
      exception of marijuana, will be excluded; patients testing positive for alcohol may be
      re-scheduled. Participants will be asked about substance use in the last 90 days and will
      fill out the Drinking Motives Questionnaire. Subjects who have not had a research physical
      exam within the last 30 days will have a physical completed. They will then be escorted to
      the scanner at 30 Bee Street.

      The study will use a double-blind placebo controlled design. Intranasal OT (n=12) or PBO
      (n=12) sprays will be administered at 11:30 am, approximately 45 min prior to the scanning
      session. This dose and timing of OT administration were selected based on the literature.

      MIST Procedure: The study will use a block design of three, 6-min runs separated by 2-min of
      rest for feedback, for a total of 24 min. During each run, participants will be exposed to
      40-sec blocks of three different conditions (rest, control, and experimental). Prior to the
      task, participants will are shown images of what the screen will look like during each
      condition. The participants will be instructed to relax during the rest condition and focus
      on the screen. During the control condition, the participants will be asked to answer math
      problems as accurately as possible but will also be told that their responses will not be
      recorded. During the experimental condition, the participants will be asked to perform the
      math task as quickly and accurately as possible. A performance bar located on the screen will
      allow them to see their performance as compared to an &quot;average&quot; person. The participants will
      be told that the average person would answer about 85% of the problems correctly; however,
      the program limits the participants' performance rate to between 35-45%. A time limit will be
      enforced throughout the experimental condition. After each run, the participants will be
      given negative feedback from the investigator.

      Blood Oxygen Level Dependent (BOLD)-fMRI Procedure: Data will be acquired on a Siemens Trio
      3T scanner in MUSC's Center for Biomedical Imaging. For co-registration and normalization of
      functional images, a high resolution T1-weighted Magnetization-Prepared Rapid Acquisition
      with Gradient Echo (MPRAGE) anatomical image will be acquired with the following parameters:
      Time of Repetition (TR)= 2100 ms, Echo Time (TE)= 4.18 ms, flip angle= 12°, field of view=
      256 mm, slice thickness= 1.0 mm. The scanning planes will be oriented parallel to the
      anterior commissure-posterior commissure line. Participants will be asked to relax and keep
      their eyes opened and fixed on a cross-hair for 6 min while resting state data are collected.
      Participants will then complete the MIST. T2*-weighted gradient-echo planar images (EPI) will
      be acquired with the following parameters: TR= 2000 ms, TE= 27 ms, flip angle= 76º, matrix 64
      x 64, field of view= 23 cm, slice thickness= 3.7 mm with no gap, with 36 slices to cover the
      entire brain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging Stress Test Task Averaged Over the Second and Third Functional Runs</measure>
    <time_frame>60 minutes following medication (oxytocin or placebo)</time_frame>
    <description>Corticolimbic functional connectivity will be determined using psychophysiological interaction (PPI) modeling. The left and right amygdala will serve as seed regions. Connectivity of each seed region with the homologous orbitofrontal cortex region will be represented as a parameter estimate, yielding one parameter estimate for right amygdala-right orbitofrontal connectivity and one parameter estimate for left amygdala-left orbitofrontal connectivity per subject.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin/alcohol use disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Alcohol use disorder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.</description>
    <arm_group_label>Oxytocin/alcohol use disorder</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution.</description>
    <arm_group_label>Placebo/Alcohol use disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 21-40.

          2. Subjects must be able to provide informed consent and function at an intellectual
             level sufficient to allow accurate completion of all assessment instruments.

          3. Meets the DSM 5 criteria for current alcohol use disorder.

          4. Reports drinking on average, at least 20 standard alcoholic drinks per week for at
             least the past three months.

          5. Currently not engaged in, and does not want treatment for, alcohol related problems.

          6. Lives within 50 miles of the study site.

          7. Subjects must consent to random assignment.

          8. Able to maintain abstinence for two days (without the aid of detoxification
             medications) as determined by self report and breathalyzer measurements Subjects must
             also have a negative breathalyzer urine drug screen at the study visit.

          9. Subjects must consent to the study visit which includes an outpatient admission to the
             Addiction Sciences Division and completing one functional magnetic resonance imaging
             (fMRI) scanning session.

        Exclusion Criteria:

          1. Currently meets DSM 5 criteria for any other psychoactive substance use disorder.

          2. Is determined

          3. Any psychoactive substance use (except marijuana and nicotine) within the last 30 days
             by self-report and urine drug screen. For marijuana, no use within the last seven days
             by verbal report and negative (or decreasing) urine THC levels.

          4. Meets DSM 5 criteria for current major depression, panic disorder,
             obsessive-compulsive disorder, post traumatic stress syndrome, bipolar affective
             disorder, schizophrenia, dissociate disorders, eating disorders, and any other
             psychotic disorder or organic mental disorder.

          5. Has current suicidal ideation or homicidal ideation.

          6. Has the need for maintenance or acute treatment with any psychoactive medication
             including anti-seizure medications and medications for ADHD.

          7. Is currently taking medication known to affect alcohol intake (e.g., disulfiram,
             naltrexone, acamprosate, topiramate).

          8. Has clinically significant medical problems such as cardiovascular, renal, GI,
             neurological (e.g. seizure disorder) or endocrine problems that would impair
             participation or limit medication ingestion.

          9. Has past history of alcohol related medical illness such as gastrointestinal bleeding,
             pancreatitis, peptic ulcer, hepatic cirrhosis or alcoholic hepatitis.

         10. Has hepatocellular disease indicated by elevations of SGPT (ALT) or SGOT (AST) greater
             than 2.5 times normal at screening.

         11. Females of childbearing potential who are pregnant (by urine HCG), nursing, or who are
             not using a reliable form of birth control.

         12. Has current charges pending for a violent crime (not including DUI related offenses).

         13. Does not have a stable living situation.

         14. Presence of ferrous metal in the body, as evidence by metal screening and self-report.

         15. Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.

         16. History of head injury with &gt;2 minutes of unconsciousness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Joseph, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addiction Sciences Division-Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <results_first_submitted>September 30, 2019</results_first_submitted>
  <results_first_submitted_qc>September 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2019</results_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03610633/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin/Alcohol Use Disorder</title>
          <description>Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
Oxytocin: The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Alcohol Use Disorder</title>
          <description>Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
Placebo: Saline solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin/Alcohol Use Disorder</title>
          <description>Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
Oxytocin: The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.</description>
        </group>
        <group group_id="B2">
          <title>Placebo/Alcohol Use Disorder</title>
          <description>Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
Placebo: Saline solution.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" lower_limit="22" upper_limit="28"/>
                    <measurement group_id="B2" value="24" lower_limit="22" upper_limit="27"/>
                    <measurement group_id="B3" value="24.6" lower_limit="22" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging Stress Test Task Averaged Over the Second and Third Functional Runs</title>
        <description>Corticolimbic functional connectivity will be determined using psychophysiological interaction (PPI) modeling. The left and right amygdala will serve as seed regions. Connectivity of each seed region with the homologous orbitofrontal cortex region will be represented as a parameter estimate, yielding one parameter estimate for right amygdala-right orbitofrontal connectivity and one parameter estimate for left amygdala-left orbitofrontal connectivity per subject.</description>
        <time_frame>60 minutes following medication (oxytocin or placebo)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin/Alcohol Use Disorder</title>
            <description>Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
Oxytocin: The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Alcohol Use Disorder</title>
            <description>Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
Placebo: Saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging Stress Test Task Averaged Over the Second and Third Functional Runs</title>
          <description>Corticolimbic functional connectivity will be determined using psychophysiological interaction (PPI) modeling. The left and right amygdala will serve as seed regions. Connectivity of each seed region with the homologous orbitofrontal cortex region will be represented as a parameter estimate, yielding one parameter estimate for right amygdala-right orbitofrontal connectivity and one parameter estimate for left amygdala-left orbitofrontal connectivity per subject.</description>
          <units>contrast of parameter estimates</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left amygdala left orbitofrontal connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.12723" spread=".103532"/>
                    <measurement group_id="O2" value="-.04836" spread=".150718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right amygdala right orbitofrontal connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".042561" spread=".155865"/>
                    <measurement group_id="O2" value="-.06624" spread=".240009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin/Alcohol Use Disorder</title>
          <description>Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
Oxytocin: The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.</description>
        </group>
        <group group_id="E2">
          <title>Placebo/Alcohol Use Disorder</title>
          <description>Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
Placebo: Saline solution.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura Lohnes</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-7709</phone>
      <email>lohnes@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

